Last reviewed · How we verify
NCT07529938: MAVA-HCM
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
trial testing mavacamten in Hypertrophic Cardiomyopathy (HCM) in 222 participants. Completed in 30 June 2025.
30 May 2025
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 222 |
| Start date | 1 January 2024 |
| Primary completion | 30 May 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- mavacamten (MAVACAMTEN) — full drug profile →
Conditions studied
- Hypertrophic Cardiomyopathy (HCM) — all drugs for Hypertrophic Cardiomyopathy (HCM) →
- Obstructive Hypertrophic Cardiomyopathy (oHCM) — all drugs for Obstructive Hypertrophic Cardiomyopathy (oHCM) →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
18 and older, any sex, with Hypertrophic Cardiomyopathy (HCM) or Obstructive Hypertrophic Cardiomyopathy (oHCM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective cohort study aims to evaluate the clinical efficacy and safety of mavacamten in adult patients with obstructive hypertrophic cardiomyopathy (oHCM). A total of 222 patients were included and categorized based on treatments received in routine clinical practice into a mavacamten group and a standard therapy group. The primary outcome is the change in resting left ventricular outflow tract (LVOT) gradient at Week 30. Secondary outcomes include changes in Valsalva LVOT gradient, New York Heart Association (NYHA) functional class, cardiac biomarkers, and echocardiographic parameters. Safety outcomes include adverse events and left ventricular systolic dysfunction. This study provides real-world evidence on the effectiveness and safety of mavacamten in Chinese patients with oHCM.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07529938
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of mavacamten
Trials testing the same drug.
- NCT07103655 — The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction · Phase 4 · not yet recruiting
- NCT06947590 — Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy · NA · active not recruiting
- NCT06023186 — Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM · recruiting
- NCT04766892 — A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT · Phase 2 · completed
- NCT03723655 — A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM · Phase 2, PHASE3 · completed
Other recruiting trials for Hypertrophic Cardiomyopathy (HCM)
Currently open trials in the same condition.
- NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
- NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
- NCT07344480 — Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM) · recruiting
- NCT06882668 — Role of Cardiovascular Imaging in the Early Diagnosis of Hypertrophic Cardiomyopathy in Women · active not recruiting
- NCT06599229 — Perfusion Abnormalities in Hypertrophic Cardiomyopathy · active not recruiting
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07529938 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07529938.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing